

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/633,460 08/04/2003		William J. Ayala	4666	
7590 06/02/2006		EXAMINER		
William J. Ayala			PERREIRA, MELISSA JEAN	
151 Bosphorus	Avenue			
Tampa, FL 33		ART UNIT	PAPER NUMBER	

1618

DATE MAILED: 06/02/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary		Α	pplication No.	Applicant(s)	Applicant(s)		
		1	0/633,460	AYALA, WILLIAM	AYALA, WILLIAM J.		
		E	xaminer	Art Unit			
			elissa Perreira	1618			
Period fo	The MAILING DATE of this commun or Reply	ication appear	s on the cover sheet	with the correspondence a	ddress		
WHIC - Exter after - If NO - Failu Any i	ORTENED STATUTORY PERIOD F CHEVER IS LONGER, FROM THE M sisions of time may be available under the provisions SIX (6) MONTHS from the mailing date of this comm period for reply is specified above, the maximum state to reply within the set or extended period for reply reply received by the Office later than three months and patent term adjustment. See 37 CFR 1.704(b).	MAILING DATE s of 37 CFR 1.136(a) nunication. atutory period will ap will, by statute, cau	OF THIS COMMUN  In no event, however, may  pply and will expire SIX (6) M  se the application to become	NICATION. a reply be timely filed ONTHS from the mailing date of this of ABANDONED (35 U.S.C. § 133).			
Status							
1)	Responsive to communication(s) file	ed on <i>04 Augu</i>	est 2003.				
2a)□			tion is non-final.				
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims						
4)⊠	Claim(s) 1-38 is/are pending in the a	application.					
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)□	Claim(s) is/are allowed.						
6)□	Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
8)⊠	Claim(s) <u>1-38</u> are subject to restriction	on and/or elec	ction requirement.				
Applicati	on Papers						
9)	The specification is objected to by th	e Examiner.					
10)	The drawing(s) filed on is/are:	: a)□ accepte	ed or b)⊡ objected t	o by the Examiner.			
	Applicant may not request that any obje	ction to the drav	wing(s) be held in abey	rance. See 37 CFR 1.85(a).			
	Replacement drawing sheet(s) including		•				
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority u	ınder 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:							
,-	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
	3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
Attachmen	• •		_				
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (F	PTO-9481	4) ∐ Interviev Paper N	w Summary (PTO-413) o(s)/Mail Date			
Notice of Draftsperson's Patent Drawing Review (P10-946)     Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)     Paper No(s)/Mail Date				f Informal Patent Application (PT	O-152)		

Application/Control Number: 10/633,460 Page 2

Art Unit: 1618

## **DETAILED ACTION**

## Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-23 are drawn to a pharmaceutical formulation sleep regulating system, classified in class 424, subclass 471.
- II. Claims 24-38 are drawn to a method of using a pharmaceutical formulation for the treatment of multiple ailments or disorders, classified in class 514, subclass 923.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case depression can be treated by an antidepressant therapy that does not include an initial release phase containing a sleep-compatible substance of the pharmaceutical formulation of group I. The pharmaceutical formulation of group I of the instant claims, does not necessarily treat depression, insomnia and tardiness as well as those listed in the instant claims and would require an undue burden of search by the office.

**Art Unit: 1618** 

3. Because these inventions are independent or distinct for the reasons given above and the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

## Conclusion

No claims are allowed at this time.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Melissa Perreira whose telephone number is 571-272-1354. The examiner can normally be reached on 9am-5pm M-F.

Application/Control Number: 10/633,460 Page 4

Art Unit: 1618

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MP May 30, 2006

MICHAEL G. HARTLEY
SUPERVISORY PATENT EXAMINER